CCHE will be taking part in the upcoming 25th annual meeting of the European Musculoskeletal Oncology Society, to be held in Bologna, Italy from May 15-16, 2012. They will be presenting two highly complex posters to represent abstracts of two major research findings related to bone tumors. The first of these is titled “Outcome and Prognostic Factors for non-Metastatic Osteosarcoma of the Extremity: The CCHE Experience” and is led by Dr. Manal Zamzam and Dr. Emad Moussa, who will be presenting their research about this particular type of localized bone tumor from a study conducted between 2007-2011. The study was carried out with highly specialized, cohesive research work teams. The study determined that overall survival rates were 87%, event-free survival rates were 70.5%, and limb salvage incidence rates were 82%. The abstract also looks into various prognostic factors, including a comparison of findings according to age, gender, tumor volume, response to chemotherapy, and bio-markers.

The presentation of these findings will reveal the effectiveness of current treatment methods and protocols, and will also statistically prove the direct correlation between age, tumor volume, level of alkaline phosphatase and the recurrence of the disease. Chances of recurrence, large tumor volume and high rates of alkaline phosphatase in the liver are less in younger patients.

The second of these two abstracts to be presented is titled “Retrospective Assessment of the Change in Intra-osseous Involvement in Ewing Sarcoma of Long Bones After Neo-Adjuvant Chemotherapy, it’s Impact on Surgical Planning and Local Control” and is led by Dr. Ahmed El Ghoneimy, a consultant in orthopedic oncology. Results of the study have proven that chemotherapy does not affect the longitude of Ewing sarcoma tumors in long bones and there “are no significant changes in the intra-osseous extent of the tumor before surgery”, despite the fact that chemotherapy is nearly always used as a pre-surgical removal treatment. The study also determined that doctors can rely on the pre-operative MRI’s given to patients with these kind of tumors to calculate safety margins prior to tumor removal.

We wish CCHE staff the best of luck at the meeting and congratulate them on their scientific achievements.